Biogen announced positive 52-week results from the Phase 2 part of its AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The data indicates continued clinical improvements and rapid onset of treatment effect, supporting the drug's potential in this indication.
Biogen announced 52-week results from the Phase 2 part of its AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The data showed continued clinical improvements and a rapid onset of treatment effect, with 27.2% of patients achieving clear or utmost clear skin at Week 52. This positive update extends the known efficacy and safety profile of litifilimab, which is a key pipeline asset for Biogen. For traders, this represents a positive long-term development for BIIB, potentially de-risking the drug's path to market and strengthening its future revenue streams, though the immediate market reaction might be moderate as this is Phase 2 data.